Respiratory Viruses in Patients With Hematological Malignancy in Boreal Autumn/Winter 2023-2024 EPICOVIDEHA-EPIFLUEHA Report /

Respiratory Viruses in Patients With Hematological Malignancy in Boreal Autumn/Winter 2023-2024 EPICOVIDEHA-EPIFLUEHA Report /

Community-acquired respiratory viral infections (CARV) significantly impact patients with hematological malignancies (HM), leading to high morbidity and mortality. However, large-scale, real-world data on CARV in these patients is limited. This study analyzed data from the EPICOVIDEHA-EPIFLUEHA regi...

Teljes leírás

Elmentve itt :
Bibliográfiai részletek
Szerzők: Salmanton-García Jon
Marchesi Francesco
Navrátil Milan
Piukovics Klára
Del Principe Maria Ilaria
Criscuolo Marianna
Bilgin Yavuz M
Fracchiolla Nicola S
Vena Antonio
Romano Alessandra
Falces-Romero Iker
Sgherza Nicola
Heras-Fernando Inmaculada
Biernat Monika M
Petzer Verena
Žák Pavel
Weinbergerová Barbora
Samarkos Michail
Erben Nurettin
van Praet Jens
López-García Alberto
Labrador Jorge
Lahmer Tobias
Drgoňa Ľuboš
Merelli Maria
Cuccaro Annarosa
Martín-Pérez Sonia
Dávila-Valls Julio
Farina Francesca
Cattaneo Chiara
Dokumentumtípus: Cikk
Megjelent: 2024
Sorozat:AMERICAN JOURNAL OF HEMATOLOGY
Tárgyszavak:
Egészségtudományok
doi:10.1002/ajh.27565

mtmt:35653108
Online Access:http://publicatio.bibl.u-szeged.hu/35431
Leíró adatok
Tartalmi kivonat:Community-acquired respiratory viral infections (CARV) significantly impact patients with hematological malignancies (HM), leading to high morbidity and mortality. However, large-scale, real-world data on CARV in these patients is limited. This study analyzed data from the EPICOVIDEHA-EPIFLUEHA registry, focusing on patients with HM diagnosed with CARV during the 2023-2024 autumn-winter season. The study assessed epidemiology, clinical characteristics, risk factors, and outcomes. The study examined 1312 patients with HM diagnosed with CARV during the 2023-2024 autumn-winter season. Of these, 59.5% required hospitalization, with 13.5% needing ICU admission. The overall mortality rate was 10.6%, varying by virus: parainfluenza (21.3%), influenza (8.8%), metapneumovirus (7.1%), RSV (5.9%), or SARS-CoV-2 (5.0%). Poor outcomes were significantly associated with smoking history, severe lymphopenia, secondary bacterial infections, and ICU admission. This study highlights the severe risk CARV poses to patients with HM, especially those undergoing active treatment. The high rates of hospitalization and mortality stress the need for better prevention, early diagnosis, and targeted therapies. Given the severe outcomes with certain viruses like parainfluenza, tailored strategies are crucial to improving patient outcomes in future CARV seasons.
ISSN:0361-8609

Hasonló tételek